Flag of the European Union EU Clinical Trials Register Help

Clinical trials for nivolumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    446 result(s) found for: nivolumab. Displaying page 6 of 23.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2021-001492-16 Sponsor Protocol Number: M21NDN Start Date*: 2021-06-16
    Sponsor Name:NKI-AVL
    Full Title: Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
    Medical condition: Patients with stage III melanoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000442-39 Sponsor Protocol Number: Neo-Nivo Start Date*: 2015-08-17
    Sponsor Name:Clinica Universidad de Navarra/Universidad de Navarra
    Full Title: PHASE II STUDY OF NEOADJUVANT NIVOLUMAB IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000461-23 Sponsor Protocol Number: CA209-627 Start Date*: 2017-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
    Medical condition: Advanced/Metastatic malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004548-40 Sponsor Protocol Number: D17-01 Start Date*: 2018-11-08
    Sponsor Name:GERCOR
    Full Title: A randomized non-comparative phase II study of Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with l...
    Medical condition: Locally advanced or metastatic Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002080-18 Sponsor Protocol Number: AIO-STO-0417 Start Date*: 2018-06-12
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs. FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction –...
    Medical condition: advanced or metastatic adenocarcinoma of the esophagogastric junction or the stomach
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002347-41 Sponsor Protocol Number: CA209-744 Start Date*: Information not available in EudraCT
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin...
    Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002676-87 Sponsor Protocol Number: CA209-9TM Start Date*: 2018-02-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Elig...
    Medical condition: Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000854-69 Sponsor Protocol Number: IPI-549-02 Start Date*: 2019-07-25
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in...
    Medical condition: Advanced Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001514-42 Sponsor Protocol Number: CA209-040 Start Date*: 2015-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I-II Dose Escalation and Expansion Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibod...
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001859-43 Sponsor Protocol Number: CA209-743 Start Date*: 2016-11-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
    Medical condition: Untreated unresectable Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) BE (Completed) DE (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002543-41 Sponsor Protocol Number: 64041757LUC2002 Start Date*: 2018-02-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Combination with Nivolumab Versus Nivolumab Monother...
    Medical condition: Advanced adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001164 Adenocarcinoma lung stage III LLT
    20.0 100000004864 10001165 Adenocarcinoma lung stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003176-16 Sponsor Protocol Number: ADP-0055-003/GOG-3084 Start Date*: 2023-07-03
    Sponsor Name:Adaptimmune LLC
    Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
    Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000039-29 Sponsor Protocol Number: CA020-016 Start Date*: 2021-11-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized Study of BMS-986207 in Combination with Nivolumab and Ipilimumab as First-line Treatment for Participants with Stage IV Non-Small Cell Lung Cancer
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002250-79 Sponsor Protocol Number: CCR4938 Start Date*: 2018-11-29
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer.
    Medical condition: Metastatic RAS wild-type colorectal cancer which has previously responded to FOLFIRI chemotherapy and Cetuximab treatment but then progressed
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002423-29 Sponsor Protocol Number: INCB24360-204 Start Date*: 2017-07-13
    Sponsor Name:incyte Corporation
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers
    Medical condition: Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003059-46 Sponsor Protocol Number: CA017-063 Start Date*: 2018-04-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Global, Open-label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
    Medical condition: Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003429-41 Sponsor Protocol Number: SOLTI-1909 Start Date*: 2021-06-23
    Sponsor Name:SOLTI
    Full Title: NiVOlumab for Luminal advanced/metastatic breast cancer to Taper ct-dnA In endocrine REsistance (VOLTAIRE trial)
    Medical condition: NiVOlumab for Luminal advanced/metastatic breast cancer to Taper ct-dnA In endocrine REsistance
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001794-32 Sponsor Protocol Number: UC-0130/1619 Start Date*: 2016-11-23
    Sponsor Name:UNICANCER
    Full Title: A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck.
    Medical condition: recurrent and/or metastatic salivary glands carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066882 Metastatic salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003286-28 Sponsor Protocol Number: CA209-436 Start Date*: 2016-04-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Medical condition: Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029606 Non-Hodgkin's lymphomas transformed recurrent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003035-28 Sponsor Protocol Number: APHP200132 Start Date*: 2022-02-22
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: " Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence " CAPTiRALL
    Medical condition: Relapsed or refractory B-ALL (any relapse after HSCT, 2nd relapse or later, refractory ALL), aged 1-25 years old, previously treated by Tisagenlecleucel (Kymriah ®), Cohort 1 presenting early loss ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:30:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA